Novo Nordisk to construct €70m manufacturing facility in Iran
Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding for the project, which is expected to
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
Gerilimzumab is directed against the IL-6 cytokine. The double-blinded and placebo controlled trial includes single and multiple ascending dose cohorts. RuiYi plans to release the trial’s results in
The study, published in The American Journal of Managed Care, suggests that this approach may help quickly identify those patients most likely to benefit from medication adherence interventions.
The DREAM Challenge is an open innovation non-profit biology project in which scientists share ideas and data. AstraZeneca’s move is aimed at advancing research into combination cancer therapy